Close

BofA/Merrill Lynch Downgrades Quest Diagnostics (DGX) to Underperform

February 23, 2015 6:29 AM EST Send to a Friend
BofA/Merrill Lynch downgraded Quest Diagnostics (NYSE: DGX) from Neutral to Underperform with a price target of $68.00 (from $71.00).Analyst Robert ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login